which shows that the drug decreases portal hypertension and improves liver perfusion in patients with cirrhosis. Complications of portal hypertension include the development of esophageal varices ...

Portal hypertension is an abnormal increase in blood pressure defined clinically as hepatic venous pressure gradient 5 mmHg in the hepatic portal vein system. Causes of portal hypertension ...

The mechanism by which patients with portal hypertension develop portal hypertensive ... of the hydrostatic pressure of the free or wedged hepatic vein in hepatic cirrhosis.

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal ...

The findings were, as expected, those of cirrhosis of the liver ("postnecrotic" type by microscopical examination) and portal hypertension. The portal pressure was equivalent to 31 cm. of saline ...

In addition, cirrhosis distorts the liver's structure, causing blood congestion in the portal vein and, ultimately, raising ...

Galectin Therapeutics (GALT) announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and ...

Proposed in the early 1980s as a solution for managing complications of portal hypertension, the percutaneous creation of ...

the diminished storage capacity of the cirrhotic liver and the affected enterohepatic circle. If we add to these conditions, the portal hypertensive enteropathy which leads to an impaired ...

Discover a new study that has examined the influence of clinical and histologic risk factors on long-term MASLD outcomes in ...

(NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH ...